8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $119M | -$82M | 39.1% | -55.8% | -$47M | $96M | $35M |
| 2024 | $114M | -$128M | 33.9% | -99.7% | -$117M | $197M | $124M |
| 2023 | $130M | -$173M | 22.2% | -130.2% | -$135M | $130M | $69M |
| 2022 | $115M | -$163M | 15.5% | -139.6% | -$154M | $96M | $73M |
| 2021 | $103M | -$132M | 7.4% | -127.2% | -$133M | $30M | $182M |
| 2020 | $50M | -$121M | -26.1% | -235.2% | -$108M | $30M | $295M |
| 2019 | $15M | -$68M | -118.1% | -466.3% | -$74M | $29M | $37M |
| 2018 | $2M | -$50M | -304.7% | -2320.0% | -$48M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $28M | -$19M | 43.4% | -60.7% | -$13M | $97M | $31M |
| Dec '25 | $29M | -$19M | 42.4% | -61.1% | -$10M | $96M | $35M |
| Sep '25 | $29M | -$18M | 39.4% | -53.7% | -$6M | $96M | $36M |
| Jun '25 | $31M | -$19M | 37.8% | -53.7% | -$5M | $95M | $40M |
| Mar '25 | $30M | -$26M | 37.2% | -55.1% | -$26M | $94M | $76M |
| Dec '24 | $29M | -$26M | 36.5% | -74.2% | -$17M | $197M | $124M |
| Sep '24 | $29M | -$28M | 34.3% | -83.2% | -$21M | $197M | $33M |
| Jun '24 | $27M | -$34M | 35.7% | -112.3% | -$33M | $197M | $38M |
| Mar '24 | $28M | -$40M | 29.2% | -131.0% | -$46M | $197M | $32M |
| Dec '23 | $31M | -$39M | 25.3% | -122.4% | -$25M | $130M | $69M |
| Sep '23 | $30M | -$46M | 23.6% | -149.7% | -$35M | $97M | $36M |
| Jun '23 | $36M | -$44M | 21.4% | -120.6% | -$29M | $97M | $36M |
| Mar '23 | $33M | -$44M | 19.2% | -129.9% | -$46M | $96M | $36M |
| Dec '22 | $32M | -$41M | 16.5% | -124.4% | -$37M | $96M | $73M |
| Sep '22 | $28M | -$41M | 15.6% | -147.7% | -$37M | $30M | $64M |
| Jun '22 | $25M | -$44M | 15.1% | -174.5% | -$41M | $30M | $75M |
| Mar '22 | $31M | -$37M | 14.5% | -119.4% | -$40M | $30M | $114M |
| Dec '21 | $28M | -$41M | 11.8% | -144.9% | -$34M | $30M | $182M |
| Sep '21 | $26M | -$30M | 11.2% | -114.5% | -$29M | $30M | $231M |
| Jun '21 | $25M | -$30M | 4.2% | -118.6% | -$32M | $30M | $274M |
How the market has priced OM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Outset Medical, Inc.'s revenue has grown 19.1% per year. These are computed facts, not advice.
As of FY2025, Outset Medical, Inc. reported $96M of total debt against $35M of cash; operating income covered interest expense -4.8×.
In FY2025, gross margin was 39.1%, operating margin -55.8%, and net margin -68.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.